Is high-risk BCR really mHSPC?? Live webinar replay
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
Is high-risk BCR really mHSPC?? Live webinar replay
-
Narrado por:
-
De:
We recently hosted another live webinar for our Gold Partners, Mundipharma, this time asking the question, "Is high-risk BCR actually metastatic prostate cancer??". It's a reasonable question! This podcast was anchored from the GU Cast studio in Melbourne by usual hosts, Renu Eapen and Declan Murphy, joined in person by Andrew Loblaw, radiation oncologist from Toronto, and online by medical oncologist Jeff Goh in Brisbane.
Best enjoyed on our YouTube channel if you want to check out the slides.
Runsheet:
- Is high-risk biochemical recurrence already metastatic prostate cancer?Declan Murphy
- Is the management of high-risk BCR and mHSPC now the same? Jeffrey Goh
- Prostate radiotherapy is the real triplet therapy; plus when should we use SBRT? Andrew Loblaw
Q&A and case discussions
This webinar was organised by our Gold Partners, Mundipharma, who also support GU Cast as Gold Partners through an unrestricted educational grant.
Todavía no hay opiniones